Phesgo Injection (10ml) is a targeted therapy used primarily in the treatment of certain types of breast cancer, specifically HER2-positive breast cancer. This innovative medication combines two monoclonal antibodies, Pertuzumab and Trastuzumab, each at a dosage of 600mg, to effectively inhibit the growth of cancer cells that overexpress the HER2 protein. By blocking the HER2 receptor, Phesgo helps to slow down or stop the proliferation of cancer cells, making it a vital component of treatment regimens for patients with this aggressive form of cancer. The injection is administered subcutaneously, providing a more convenient option compared to traditional intravenous therapies, which can enhance patient compliance and comfort. Phesgo is typically used in conjunction with chemotherapy to maximize its effectiveness, and its formulation is designed to ensure optimal absorption and therapeutic action.